NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$25.31 +0.26 (+1.04 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$25.05
Today's Range$24.80 - $26.23
52-Week Range$15.15 - $29.98
Volume64,000 shs
Average Volume143,984 shs
Market Capitalization$842.56 million
P/E Ratio-8.46
Dividend YieldN/A
BetaN/A

About Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals logoDeciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive DCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400

Debt

Debt-to-Equity Ratio0.01
Current Ratio11.12
Quick Ratio11.12

Price-To-Earnings

Trailing P/E Ratio-8.46
Forward P/E Ratio-9.41
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.05 per share
Price / Book5.01

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees65
Outstanding Shares32,590,000

Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals (NASDAQ:DCPH) issued its earnings results on Tuesday, May, 8th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.62) by $0.04. View Deciphera Pharmaceuticals' Earnings History.

What price target have analysts set for DCPH?

6 Wall Street analysts have issued 1 year price objectives for Deciphera Pharmaceuticals' shares. Their forecasts range from $30.00 to $57.00. On average, they expect Deciphera Pharmaceuticals' share price to reach $43.3333 in the next year. View Analyst Ratings for Deciphera Pharmaceuticals.

Who are some of Deciphera Pharmaceuticals' key competitors?

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the folowing people:
  • Dr. Michael D. Taylor, Pres, CEO & Director (Age 63)
  • Dr. Oliver Rosen, Chief Medical Officer (Age 54)
  • Mr. Christopher J. Morl, Chief Bus. Officer (Age 59)
  • Dr. Daniel L. Flynn, Founder & Chief Scientific Officer (Age 63)
  • Mr. Thomas Patrick Kelly, Chief Financial Officer (Age 47)

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

When did Deciphera Pharmaceuticals' lock-up period expire?

Deciphera Pharmaceuticals' lock-up period expired on Tuesday, March 27th. Deciphera Pharmaceuticals had issued 7,500,000 shares in its IPO on September 28th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Has Deciphera Pharmaceuticals been receiving favorable news coverage?

News headlines about DCPH stock have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Deciphera Pharmaceuticals earned a news impact score of 0.22 on Accern's scale. They also gave media coverage about the company an impact score of 46.34 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (2.52%), BlackRock Inc. (1.53%), Opaleye Management Inc. (1.12%), Lord Abbett & CO. LLC (1.07%), JPMorgan Chase & Co. (0.88%) and Millennium Management LLC (0.74%). View Institutional Ownership Trends for Deciphera Pharmaceuticals.

Which institutional investors are selling Deciphera Pharmaceuticals stock?

DCPH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Sphera Funds Management LTD. and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for Deciphera Pharmaceuticals.

Which institutional investors are buying Deciphera Pharmaceuticals stock?

DCPH stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Redmile Group LLC, BlackRock Inc., JPMorgan Chase & Co., Eversept Partners LLC, Lord Abbett & CO. LLC, A.R.T. Advisors LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Deciphera Pharmaceuticals.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $25.31.

How big of a company is Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has a market capitalization of $842.56 million. The company earns $-50,280,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Deciphera Pharmaceuticals employs 65 workers across the globe.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]


MarketBeat Community Rating for Deciphera Pharmaceuticals (DCPH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Deciphera Pharmaceuticals (NASDAQ:DCPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Deciphera Pharmaceuticals in the last 12 months. Their average twelve-month price target is $43.3333, suggesting that the stock has a possible upside of 71.21%. The high price target for DCPH is $57.00 and the low price target for DCPH is $30.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $43.3333$43.3333$43.3333$43.40
Price Target Upside: 71.21% upside50.99% upside50.99% upside115.38% upside

Deciphera Pharmaceuticals (NASDAQ:DCPH) Consensus Price Target History

Price Target History for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals (NASDAQ:DCPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018B. RileyLower Price TargetBuy ➝ Buy$52.00 ➝ $43.00HighView Rating Details
10/23/2017NomuraInitiated CoverageBuy ➝ Buy$57.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$35.00N/AView Rating Details
10/23/2017InstinetInitiated CoverageBuy$57.00N/AView Rating Details
10/23/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$38.00N/AView Rating Details
10/23/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$30.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Deciphera Pharmaceuticals (NASDAQ:DCPH) Earnings History and Estimates Chart

Earnings by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals (NASDAQ:DCPH) Earnings Estimates

2018 EPS Consensus Estimate: ($2.76)
2019 EPS Consensus Estimate: ($3.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.62)($0.62)($0.62)
Q2 20181($0.66)($0.66)($0.66)
Q3 20181($0.71)($0.71)($0.71)
Q4 20181($0.77)($0.77)($0.77)
Q1 20191($0.79)($0.79)($0.79)
Q2 20191($0.82)($0.82)($0.82)
Q3 20191($0.85)($0.85)($0.85)
Q4 20191($0.88)($0.88)($0.88)

Deciphera Pharmaceuticals (NASDAQ DCPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.62)($0.66)ViewN/AView Earnings Details
3/28/2018Q4 2017($0.4270)($0.62)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.5450)($5.85)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Deciphera Pharmaceuticals (NASDAQ:DCPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Deciphera Pharmaceuticals (NASDAQ DCPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 20.61%
Institutional Ownership Percentage: 48.73%
Insider Trading History for Deciphera Pharmaceuticals (NASDAQ:DCPH)
Institutional Ownership by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals (NASDAQ DCPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2017New Leaf Venture Management IiMajor ShareholderBuy375,000$17.00$6,375,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Deciphera Pharmaceuticals (NASDAQ DCPH) News Headlines

Source:
DateHeadline
Deciphera Pharmaceuticals (DCPH) Given Consensus Recommendation of "Buy" by AnalystsDeciphera Pharmaceuticals (DCPH) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 24 at 7:34 PM
Xiana to Acquire Producing Copper Operation in Chile and Announces Financing for up to C$20 MillionXiana to Acquire Producing Copper Operation in Chile and Announces Financing for up to C$20 Million
finance.yahoo.com - May 22 at 4:18 PM
Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a DirectorDeciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director
finance.yahoo.com - May 21 at 9:27 AM
Zacks: Analysts Expect Deciphera Pharmaceuticals (DCPH) to Post -$0.67 EPSZacks: Analysts Expect Deciphera Pharmaceuticals (DCPH) to Post -$0.67 EPS
www.americanbankingnews.com - May 20 at 11:14 PM
Deciphera Pharmaceuticals (DCPH) Downgraded to Hold at BidaskClubDeciphera Pharmaceuticals (DCPH) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - May 15 at 1:31 PM
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor ConferencesDeciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
finance.yahoo.com - May 14 at 10:34 AM
FY2018 EPS Estimates for Deciphera Pharmaceuticals (DCPH) Cut by B. RileyFY2018 EPS Estimates for Deciphera Pharmaceuticals (DCPH) Cut by B. Riley
www.americanbankingnews.com - May 11 at 10:52 AM
Deciphera Pharmaceuticals (DCPH) PT Lowered to $43.00 at B. RileyDeciphera Pharmaceuticals (DCPH) PT Lowered to $43.00 at B. Riley
www.americanbankingnews.com - May 9 at 6:08 PM
Deciphera Pharmaceuticals (DCPH) Releases Quarterly  Earnings Results, Misses Estimates By $0.04 EPSDeciphera Pharmaceuticals (DCPH) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 9 at 3:16 PM
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2018 Financial ResultsDeciphera Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 4:19 PM
Financial Contrast: Verastem (VSTM) and Deciphera Pharmaceuticals (DCPH)Financial Contrast: Verastem (VSTM) and Deciphera Pharmaceuticals (DCPH)
www.americanbankingnews.com - May 7 at 1:08 AM
Deciphera Pharmaceuticals (DCPH) Upgraded to Buy by BidaskClubDeciphera Pharmaceuticals (DCPH) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - May 5 at 12:29 AM
Deciphera Pharmaceuticals (DCPH) Upgraded to "Hold" by ValuEngineDeciphera Pharmaceuticals (DCPH) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - May 3 at 7:47 PM
Deciphera Pharmaceuticals (DCPH) Expected to Announce Earnings of -$0.64 Per ShareDeciphera Pharmaceuticals (DCPH) Expected to Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - May 3 at 6:52 PM
Deciphera Pharmaceuticals (DCPH) Receives Consensus Recommendation of "Buy" from BrokeragesDeciphera Pharmaceuticals (DCPH) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 29 at 7:20 PM
Deciphera Pharmaceuticals (DCPH) Cut to Buy at BidaskClubDeciphera Pharmaceuticals (DCPH) Cut to Buy at BidaskClub
www.americanbankingnews.com - April 26 at 1:31 PM
Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 2018 American Society for Clinical Oncology (ASCO) Annual MeetingDeciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 2018 American Society for Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 25 at 4:29 PM
Preclinical Data Demonstrate That Deciphera Pharmaceuticals DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in ...Preclinical Data Demonstrate That Deciphera Pharmaceuticals' DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in ...
www.businesswire.com - April 17 at 4:42 PM
Preclinical Data Demonstrate That Deciphera Pharmaceuticals DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational AgentsPreclinical Data Demonstrate That Deciphera Pharmaceuticals' DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents
finance.yahoo.com - April 17 at 9:58 AM
-$0.64 Earnings Per Share Expected for Deciphera Pharmaceuticals (DCPH) This Quarter-$0.64 Earnings Per Share Expected for Deciphera Pharmaceuticals (DCPH) This Quarter
www.americanbankingnews.com - April 16 at 11:14 AM
Deciphera Pharmaceuticals (DCPH) Upgraded at BidaskClubDeciphera Pharmaceuticals (DCPH) Upgraded at BidaskClub
www.americanbankingnews.com - April 12 at 10:23 AM
Deciphera Pharmaceuticals (DCPH) Coverage Initiated at InstinetDeciphera Pharmaceuticals (DCPH) Coverage Initiated at Instinet
www.americanbankingnews.com - April 6 at 12:23 PM
JMP Securities Initiates Coverage on Deciphera Pharmaceuticals (DCPH)JMP Securities Initiates Coverage on Deciphera Pharmaceuticals (DCPH)
www.americanbankingnews.com - April 6 at 11:00 AM
Deciphera Pharmaceuticals (DCPH) Receives New Coverage from Analysts at JPMorgan ChaseDeciphera Pharmaceuticals (DCPH) Receives New Coverage from Analysts at JPMorgan Chase
www.americanbankingnews.com - April 6 at 11:00 AM
Deciphera Pharmaceuticals (DCPH) Stock Rating Lowered by Zacks Investment ResearchDeciphera Pharmaceuticals (DCPH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 4 at 9:36 PM
Deciphera Pharmaceuticals Inc (DCPH) Receives Average Recommendation of "Buy" from BrokeragesDeciphera Pharmaceuticals Inc (DCPH) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 7:10 PM
Piper Jaffray Analysts Cut Earnings Estimates for Deciphera Pharmaceuticals Inc (DCPH)Piper Jaffray Analysts Cut Earnings Estimates for Deciphera Pharmaceuticals Inc (DCPH)
www.americanbankingnews.com - April 4 at 7:58 AM
Deciphera Pharmaceuticals (DCPH) Rating Increased to Hold at BidaskClubDeciphera Pharmaceuticals (DCPH) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 30 at 10:36 PM
 Analysts Expect Deciphera Pharmaceuticals Inc (DCPH) to Post -$0.40 Earnings Per Share Analysts Expect Deciphera Pharmaceuticals Inc (DCPH) to Post -$0.40 Earnings Per Share
www.americanbankingnews.com - March 30 at 1:19 PM
BidaskClub Upgrades Deciphera Pharmaceuticals (DCPH) to "Buy"BidaskClub Upgrades Deciphera Pharmaceuticals (DCPH) to "Buy"
www.americanbankingnews.com - March 30 at 10:58 AM
Deciphera Pharmaceuticals (DCPH) Releases  Earnings ResultsDeciphera Pharmaceuticals (DCPH) Releases Earnings Results
www.americanbankingnews.com - March 29 at 7:38 AM
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter 2017 Financial Results and Corporate HighlightsDeciphera Pharmaceuticals, Inc. Announces Fourth Quarter 2017 Financial Results and Corporate Highlights
finance.yahoo.com - March 28 at 4:16 PM
Deciphera Pharmaceuticals Incs Lock-Up Period Set To End  on March 27th (NASDAQ:DCPH)Deciphera Pharmaceuticals Inc's Lock-Up Period Set To End on March 27th (NASDAQ:DCPH)
www.americanbankingnews.com - March 20 at 1:16 AM
BidaskClub Lowers Deciphera Pharmaceuticals (DCPH) to BuyBidaskClub Lowers Deciphera Pharmaceuticals (DCPH) to Buy
www.americanbankingnews.com - March 17 at 6:14 PM
Deciphera Pharmaceuticals (DCPH) to Report Clinical and Preclinical Data with DCC-2618 at AACRDeciphera Pharmaceuticals (DCPH) to Report Clinical and Preclinical Data with DCC-2618 at AACR
www.streetinsider.com - March 16 at 9:59 AM
Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Recommendation of "Buy" by BrokeragesDeciphera Pharmaceuticals Inc (DCPH) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 10 at 9:42 PM
Hudson Bay Capital Management LP Raises Holdings in Deciphera Pharmaceuticals Inc (DCPH)Hudson Bay Capital Management LP Raises Holdings in Deciphera Pharmaceuticals Inc (DCPH)
www.americanbankingnews.com - February 28 at 1:54 PM
Deciphera Pharma Scores A Sell-Side RecommendationDeciphera Pharma Scores A Sell-Side Recommendation
finance.yahoo.com - February 16 at 4:27 PM
Deciphera Pharmaceuticals (DCPH) Coverage Initiated at B. RileyDeciphera Pharmaceuticals (DCPH) Coverage Initiated at B. Riley
www.americanbankingnews.com - February 16 at 9:52 AM
Deciphera Pharmaceuticals Inc (DCPH) Receives Consensus Rating of "Buy" from BrokeragesDeciphera Pharmaceuticals Inc (DCPH) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 13 at 9:24 PM
Deciphera Pharmaceuticals (DCPH) Stock Rating Upgraded by BidaskClubDeciphera Pharmaceuticals (DCPH) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 10 at 12:14 PM
Deciphera Pharmaceuticals (DCPH) Downgraded to "Hold" at Zacks Investment ResearchDeciphera Pharmaceuticals (DCPH) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 11:50 PM
Deciphera Pharmaceuticals (DCPH) Rating Increased to Buy at Zacks Investment ResearchDeciphera Pharmaceuticals (DCPH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 9 at 8:58 PM
Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study)Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study)
finance.yahoo.com - January 4 at 8:49 AM
Deciphera Pharmaceuticals, Inc. to Present at the 36th Annual J.P. Morgan Healthcare ConferenceDeciphera Pharmaceuticals, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 8:02 AM
Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Recommendation of "Buy" by AnalystsDeciphera Pharmaceuticals Inc (DCPH) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 26 at 12:41 AM
Deciphera Pharmaceuticals (DCPH) Upgraded by Zacks Investment Research to BuyDeciphera Pharmaceuticals (DCPH) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - December 25 at 8:40 PM
Deciphera Pharmaceuticals, Inc. Added to Russell 2000® IndexDeciphera Pharmaceuticals, Inc. Added to Russell 2000® Index
finance.yahoo.com - December 18 at 8:54 AM
Zacks: Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 15 at 5:52 AM
Deciphera Pharmaceuticals (DCPH) vs. Its Competitors Head to Head ContrastDeciphera Pharmaceuticals (DCPH) vs. Its Competitors Head to Head Contrast
www.americanbankingnews.com - December 8 at 5:14 PM

SEC Filings

Deciphera Pharmaceuticals (NASDAQ:DCPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Deciphera Pharmaceuticals (NASDAQ:DCPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Deciphera Pharmaceuticals (NASDAQ DCPH) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.